Right ventricular expression of extracellular matrix proteins, matrix-metalloproteinases, and their inhibitors over a period of 3 years after heart transplantation

Virchows Archiv

Volumn 448, Issue 2, 2006, Pages 184-194

  Schupp, D J ^a   Huck, B P ^a   Sykora, J ^a   Flechtenmacher, C ^a   Gorenflo, M ^a   Koch, A ^a   Sack, F U ^a   Haass, M ^a   Katus, H A ^a   Ulmer, H E ^a   Hagl, S ^a   Otto, H F ^a   Schnabel, P A ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Connective tissue fibers; Extracellular matrix; Heart transplantation; Matrix metalloproteinases; Tissue inhibitors

Indexed keywords

COLLAGEN TYPE 1; COLLAGEN TYPE 3; COLLAGEN TYPE 4; FIBRONECTIN; GELATINASE B; GLYCOPROTEIN; LAMININ; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; NEUTROPHIL COLLAGENASE; SCLEROPROTEIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONCENTRATION (PARAMETERS); CONNECTIVE TISSUE; CONTROLLED STUDY; FEMALE; HEART MUSCLE BIOPSY; HEART TRANSPLANTATION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MORPHOMETRICS; PHYSIOLOGY; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; STAINING; STRESS; TIME SERIES ANALYSIS;

ADOLESCENT; ADULT; ANTIGENS, CD; CHILD; EXTRACELLULAR MATRIX PROTEINS; FEMALE; HEART TRANSPLANTATION; HEART VENTRICLES; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MATRIX METALLOPROTEINASE 8; MATRIX METALLOPROTEINASE 9; MATRIX METALLOPROTEINASES; MIDDLE AGED; MYOCARDIUM; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASES;

EID: 32544433930     PISSN: 09456317     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00428-005-0050-z     Document Type: Article

References (47)

1. Amann K, Kronenberg G, Gehlen F, Wessels S, Orth S, Muenter K, Ehmke H, Mall G, Ritz E (1998) Cardiac remodelling in experimental renal failure - an immunohistochemical study. Nephrol Dial Transplant 13:1958-1966
2. Armstrong AT, Binkley PF, Baker PB, Myerowitz PD, Leier CV (1998) Quantitative investigation of cardiomyocyte hypertrophy and myocardial fibrosis over 6 years after cardiac transplantation. J Am Coll Cardiol 32:704-710
3. Asatsuma M, Ito S, Watanabe M, Takeishi H, Nomura S, Wada Y, Nakano M, Gejyo F, Igarashi A (2004) Increase in the ratio of matrix metalloproteinase-9 to tissue inhibitor of metalloproteinase-1 in saliva from patients with primary Sjogren's syndrome. Clin Chim Acta 345:99-104
4. Bosman FT, Stamenkovic I (2004) Functional structure and composition of the extracellular matrix. J Pathol 200:423-428
5. Calzolari V, Angelini A, Basso C, Livi U, Rossi L, Thiene G (1999) Histologic findings in the conduction system after cardiac transplantation and correlation with electrocardiographic findings. Am J Cardiol 84:756-759
6. Cleutjens JPM, Verluyten MJA, Smits JFM, Daemen MJAP (1995) Collagen remodeling after myocardial infarction in the rat heart. Am J Pathol 147:325-338
7. Coito AJ, Binder J, de Sousa M, Kupiec-Weglinski JW (1994) The expression of extracellular matrix proteins during accelerated rejection of cardiac allografts in sensitized rats. Transplantation 57:599-605
8. Coito AJ, Binder J, Brown LF, de Sousa M, Van de Water L, Kupiec-Weglinski JW (1995) Anti-TNF-alpha treatment down-regulates the expression of fibronectin and decreases cellular infiltration of cardiac allografts in rats. J Immunol 154(6): 2949-2958
9. Coito AJ, Kupiec-Weglinski JW (2000) Extracellular matrix proteins in organ transplantation. Transplantation 69:2465-2473
10. Coker ML, Thomas CV, Clair MJ, Hendrick JW, Krombach RS, Galis ZS, Spinale FG (1998) Myocardial matrix metalloproteinase activity and abundance with congestive heart failure. Am J Physiol 274:H1516-H1523
11. Coker ML, Doscher MA, Thomas CV, Galis ZS, Spinale FG (1999) Matrix metalloproteinase synthesis and expression in isolated LV myocyte preparations. Am J Physiol 277:H777-H787
12. Edep ME, Shirani J, Wolf P, Brown DL (2000) Matrix metalloproteinase expression in nonrheumatic aortic stenosis. Cardiovasc Pathol 9:281-286
13. Ekekezie II, Thibeault DW, Simon SD, Norberg M, Merrill JD, Ballard RA, Ballard PL, Truog WE (2004) Low levels of tissue inhibitors of metalloproteinases with a high matrix metalloproteinase-9/tissue inhibitor of metalloproteinase 1 ratio are present in tracheal aspirate fluid of infants who develop chronic lung disease. Pediatrics 113(6):1709-1714
14. Gunja-Smith Z, Morales AR, Romanelli R, Woessner JF Jr (1996) Remodeling of human myocardial collagen in idiopathic dilated cardiomyopathy. Am J Pathol 148:1639-1648
15. Herpel E, Singer S, Flechtenmacher C, Pritsch M, Sack FU, Hagl S, Katus HA, Haass M, Otto HF, Schnabel PA (2005) Extracellular matrix proteins and matrix metalloproteinases differ between various right and left ventricular sites in end-stage cardiomyopathies. Virchows Arch 446:369-378
16. Kabashima A, Yao T, Sugimachi K, Tsuneyoshi M (2002) Relationship between biologic behavior and phenotypic expression in intramucosal gastric carcinomas. Human Pathol 33:80-86
17. Kim HE, Dalai SS, Young E, Legato MJ, Weisfeldt ML, D'Armiento J (2000) Disruption of the myocardial extracellular matrix leads to cardiac dysfunction. J Clin Invest 106:857-866
18. Kinoshita T, Sato H, Okada A, Ohuchi E, Imai K, Okada Y, Seiki M (1998) TIMP-2 promotes activation of progelatinase A by membrane-type 1 matrix metalloproteinase immobilized on agarose beads. J Biol Chem 273:16098-16103
19. Lee RT, Libby P (2000) Matrix metalloproteinases: not-so-innocent bystanders in heart failure. J Clin Invest Med 106: 827-828
20. Li YY, Feldman AM, Sun Y, McTiernan CF (1998) Differential expression of tissue inhibitors of metalloproteinases in the failing human heart. Circulation 98:1728-1734
21. Li YY, Feng YQ, Kadokami T, McTiernan CF, Draviam R, Watkins SC, Feldman AM (2000) Myocardial extracellular matrix remodeling in transgenic mice overexpressing tumor necrosis factor alpha can be modulated by anti-tumor necrosis factor alpha therapy. Proc Natl Acad Sci U S A 97:12746-12751
22. Libby P, Lee RT (2000) Matrix matters. Circulation 102:1874-1876
23. Maggard MA, Ke B, Wang T, Kaldas F, Seu P, Busuttil RW, Imagawa DK (1998) Effects of pravastatin on chronic rejection of rat cardiac allografts. Transplantation 65:149-155
24. Mirastschijski U, Impola U, Jahkola T, Karlsmark T, Agren MS, Saarialho-Kere U (2002) Ectopic localization of matrix metalloproteinase-9 in chronic cutaneous wounds. Human Pathol 33:355-364
25. Nagase H (1997) Activation mechanisms of matrix metalloproteinases. J Biol Chem 378:151-160
26. Ogata Y, Enghild JJ, Nagase H (1992) Matrix metalloproteinase 3 (stromelysin) activates the precursor for the human matrix metalloproteinase 9. J Biol Chem 267:3581-3584
27. Peterson JT, Li H, Dillon L, Bryant JW (2000) Evolution of matrix metalloprotease and tissue inhibitor expression during heart failure progression in the infarcted rat. Cardiovasc Res 46:307-315
28. Pickering JG, Boughner DR (1990) Fibrosis in the transplanted heart and its relation to donor ischemic time: assessment with polarized light microscopy and digital image analysis. Circulation 81:949-958
29. Rohde LE, Ducharme A, Arroyo LH, Aikawa M, Sukhova GH, Lopez-Anaya A, McClure KF, Mitchell PG, Libby P, Lee RT (1999) Matrix metalloproteinase inhibition attenuates early left ventricular enlargement after experimental myocardial infarction in mice. Circulation 99:3063-3070
30. Ross RS, Borg TK (2001) Integrins and the myocardium. Circ Res 88:1112-1119
31. Schowengerdt KO, Fricker FJ, Bahjat KS, Kuntz ST (2000) Increased expression of the lymphocyte early activation marker CD69 in peripheral blood correlates with histologic evidence of cardiac allograft rejection. Transplantation 69:2102-2107
32. Schupp DJ, Sykora J, Flechtenmacher CH, Huck BP, Koch A, Sack F-U, Haass M, Brockmeier K, Ulmer HE, Hagel S, Otto HF, Schnabel PA (2002) Right ventricular expression of laminin, fibronectin and collagens I, III, and IV over a period of 3 years after heart transplantation. Pathologica 94:71
33. Spinale FG, Coker ML, Thomas CV, Walker JD, Mukherjee R, Hebbar L (1998) Time-dependent changes in matrix metalloproteinase activity and expression during the progression of congestive heart failure: relation to ventricular and myocyte function. Circ Res 82:482-495
34. Spinale FG (2002) Matrix metalloproteinases-regulation and dysregulation in the failing heart. Circ Res 90:520-530
35. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI (1995) Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. Biol Chem 270:5331-5338
36. Suzuki J, Isobe M, Kawauchi M, Endoh M, Amano J, Takamoto S (2000) Altered expression of matrix metalloproteinases and tissue inhibitors of metalloproteinases in acutely rejected myocardium and coronary arteriosclerosis in cardiac allografts of nonhuman primates. Transpl Int 13:106-113
37. Sweet DG, Curley AE, Chesshyre E, Pizzotti J, Wilbourn MS, Halliday HL, Warner JA (2004) The role of matrix metalloproteinase -9 and -2 in development of neonatal chronic lung disease. Acta Paediatr 93:791-796
38. Tamarina NA, McMillan WD, Shively VP, Pearce WH (1997) Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 122:264-272
39. Thomas CV, Coker ML, Zellner JL, Handy JR, Crumbley AF, Spinale FG (1998) Increased matrix metalloproteinase activity and selective upregulation in LV myocardium from patients with end-stage dilated cardiomyopathy. Circulation 97:1708-1715
40. Tyagi SC, Campbell SE, Reddy HK, Tjahja E, Voelker DJ (1996) Matrix metalloproteinase activity expression in infarcted, noninfarcted and dilated cardiomyopathic human hearts. Mol Cell Biochem 155:13-21
41. Tyagi SC, Kumar SG, Haas SJ, Reddy HK, Voelker DJ, Hayden MR, Demmy TL, Schmaltz RA, Curtis JJ (1996) Post-transcriptional regulation of extracellular matrix metalloproteinases in human heart end-stage failure secondary to ischemic cardiomyopathy. J Mol Cell Cardiol 28:1415-1428
42. Tyagi SC (1998) Extracellular matrix dynamics in heart failure: a prospect for gene therapy. J Cell Biochem 68:403-410
43. Weibel ER (1979) Stereological methods, vol 1. Practical methods for biological morphometry. Academic, London
44. Weibel ER (1980) Stereological methods, vol 2. Theoretical foundations. Academic, London
45. Winters GL, Loh E, Schoen FJ (1995) Natural history of focal moderate cardiac allograft rejection. Circulation 91:1975-1980
46. Woessner JF (1991) Matrix metalloproteinases and their inhibitors in connective tissue remodeling. FASEB J 5:2145-2154
47. Yokoseki O, Yazuki Y, Suzuki J, Imamura H, Takenaka H, Isobe M (2000) Association of matrix metalloproteinase expression and left ventricular function in idiopathic dilated cardiomyopathy. Circ J 64:352-357